Tamoxifen Targets Wisp2 to Impair Subcutaneous Adipose Progenitor Self-Renewal and Adipogenic Differentiation

ABSTRACT: Prolonged tamoxifen treatment for estrogen receptor positive breast cancer disrupts estrogen receptor signaling in subcutaneous adipocytes and downregulates Wnt1-inducible signaling pathway protein 2 (Wisp2/Ccn5), a key regulator of progenitor cell maintenance. The resulting reduction in cell proliferation, impaired self renewal of progenitors, and reduced adipogenic differentiation by tamoxifen prevents healthy adipose tissue expansion. This study reveals a molecular mechanism for the effects of tamoxifen on adipocyte precursors. To evaluate and compare changes in gene expression profiles, we performed global transcriptomic and pathway analyses following treatment of cells with estradiol or 4OH-tamoxifen, or in cells with or without Wisp2.

ORGANISM(S): Mus musculus

PROVIDER: GSE318553 | GEO | 2026/09/27

REPOSITORIES: GEO